The global pyrogen testing market size is projected to reach USD 1,689 million by 2025 from USD 927 million in 2020, at a CAGR of 12.7%. Market growth is driven by the growing focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology industries, rising prevalence of chronic diseases, the growing awareness of food safety, and the rising incidence of infectious diseases and increasing frequency of pandemics.
Opportunity: Emerging markets offer lucrative opportunities
Countries across the APAC are highly lucrative markets for the life sciences industry. For instance, India has been taking significant initiatives, including encouraging public-private partnerships (PPPs) in biopharmaceutical R&D projects, to establish itself as the world’s leading major biopharmaceutical innovation hub. South Korea is also taking initiatives to become a global biotech hub with a focus on biosimilars, vaccine production, and stem cell therapies. The growing demand for remedial treatments for life-threatening diseases, such as cancer and diabetes, highlights the need for drug R&D and thereby the demand for pyrogen testing kits for effective quality testing and control.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255266155
“In 2019, assays, kits, & reagents segment accounted for the largest share of the pyrogen testing market, by product & service”
Based on product & service, the pyrogen testing market is segmented into assays, kits, and reagents; instruments; and services. The assays, kits, & reagents segment accounted for the largest share in the pyrogen testing market in 2019. The rising preference for kit-based testing and the frequent requirement of assays, kits, and reagents in large numbers as compared to instruments are the major factors driving the growth of this segment.
In 2019, LAL tests segment accounted for the largest share in the market, by test type
The pyrogen testing market is segmented into LAL tests, in vitro tests, and rabbit tests based on test type. In 2019, the LAL tests segment accounted for the largest share. This can be attributed to the rapid growth in the pharmaceutical and biotechnology industries, increasing demand for medical devices, increasing health standards, rising need for innovative laboratory testing procedures, and the growing drug pipelines.
North America is the largest regional market for pyrogen testing
The global pyrogen testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the global pyrogen testing market. The North American pyrogen testing market's growth can be attributed to the high spending on pharmaceutical and biopharmaceutical research, increasing pharmaceutical drug pipelines, a growing number of drug approvals, and rising consumer awareness about product safety.
Some key players in the pyrogen testing market (2020- 2025)
Charles River Laboratories, Inc.(US)
Thermo Fisher Scientific, Inc. (US)
Pyrogen Testing Market
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ PYROGEN TESTING MARKET
Pyrogen Testing Market by Product & Service (Assays, Kits, Reagents,
Instruments, Services), Test Type (LAL, Chromogenic, Turbidimetric,
Gel Clot, In Vitro, Rabbit), End User (Pharmaceutical, Biotechnology,
Medical Device), Region - Global Forecast to 2025
[170 Pages Report] The global pyrogen testing market size is projected to reach USD 1,689 million
by 2025 from USD 927 million in 2020, at a CAGR of 12.7%. Market growth is driven by the growing
focus on personalized medicine, increasing R&D in the pharmaceutical and biotechnology
industries, rising prevalence of chronic diseases, the growing awareness of food safety, and the
rising incidence of infectious diseases and increasing frequency of pandemics.
To know about the assumptions considered for the study, Request for Free Sample Report
COVID-19 Impact on Global Pyrogen Testing Market
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus.
Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 has
moved from a regional crisis to a global pandemic in just a matter of a few weeks. With the World
Health Organization (WHO) officially declared the outbreak of COVID-19, a pandemic, a mix of
established pharmaceutical and biopharmaceutical companies, as well as small startups, have
stepped forward to develop treatments and vaccines that target the infection caused by the novel
coronavirus. According to the WHO, there are 70 vaccine candidates under development at present,
and three candidates are already being tested in human trials. The pandemic's economic and social
burden has prompted government bodies globally to increase support for vaccine development,
which has led to an increase in the adoption of pyrogen testing products for COVID-19 research. As